D 3263

Drug Profile

D 3263

Alternative Names: D-3263; D-3263 HCl; EC D-3263 HCl; Enteric coated D-3263 HCl; TRPM8

Latest Information Update: 28 Apr 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dendreon Corporation
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Apoptosis stimulants; TRPM8 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Benign prostatic hyperplasia; Solid tumours

Most Recent Events

  • 31 Dec 2013 Suspended - Phase-I for Solid tumours in USA (PO)
  • 31 Dec 2013 Suspended - Preclinical for Benign prostatic hyperplasia in USA (PO)
  • 01 Dec 2011 Dendreon completes its phase I trial for Solid tumours in USA (NCT00839631)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top